Menin Inhibition Shows Potential for Precision Therapy in AML with Dr. Mollie Leoni Kura Oncology
Release Date: 06/25/2024
Empowered Patient Podcast
Tom Kim, Chief Medical Officer at Sound Long-Term Care Management, discusses the role of accountable care organizations, ACOs, in improving healthcare for the long-term care population. The unique complexities and challenges of these patients include multiple medical conditions, frequent hospitalizations, and fragmented care. By using predictive analytics, telemedicine, and value-based care principles to deliver more coordinated care, patients are avoiding hospitalizations, receiving higher-quality care, and experiencing reduced costs. Tom explains, "So, in essence, an accountable care...
info_outlineEmpowered Patient Podcast
Tom Kim, Chief Medical Officer at Sound Long-Term Care Management, discusses the role of accountable care organizations, ACOs, in improving healthcare for the long-term care population. The unique complexities and challenges of these patients include multiple medical conditions, frequent hospitalizations, and fragmented care. By using predictive analytics, telemedicine, and value-based care principles to deliver more coordinated care, patients are avoiding hospitalizations, receiving higher-quality care, and experiencing reduced costs. Tom explains, "So, in essence, an accountable care...
info_outlineEmpowered Patient Podcast
Lisa Israelovitch, Co-Founder and CEO of AssistIQ, is addressing the challenges in healthcare supply chain management caused by a lack of accurate data on supplies used across the care facility, which leads to operational inefficiencies and financial losses. The previous methods of tracking have often been manual and unreliable, involving product stickers, barcode readers, and manual data entry. Using computer vision and AI to automatically see, track, and document every product used is improving data accuracy, saving clinicians' time, enabling inventory tracking and product expiration...
info_outlineEmpowered Patient Podcast
Lisa Israelovitch, Co-Founder and CEO of AssistIQ, is addressing the challenges in healthcare supply chain management caused by a lack of accurate data on supplies used across the care facility, which leads to operational inefficiencies and financial losses. The previous methods of tracking have often been manual and unreliable, involving product stickers, barcode readers, and manual data entry. Using computer vision and AI to automatically see, track, and document every product used is improving data accuracy, saving clinicians' time, enabling inventory tracking and product expiration...
info_outlineEmpowered Patient Podcast
Ronen Eckhouse, Co-Founder and CEO of Rapid Medical, identifies the limitations of current stroke treatments, which are primarily effective for large vessel occlusions. The Rapid Medical TIGERTRIEVER device is designed to safely and effectively treat strokes and remove clots in smaller vessels deeper in the brain. The unique adjustability of the device allows physicians to control the size and force during a procedure, allowing for precise and safer clot removal in complex anatomies. Ronen explains, "So the quicker or the less time there is between the stroke and the ability to...
info_outlineEmpowered Patient Podcast
Ronen Eckhouse, Co-Founder and CEO of Rapid Medical, identifies the limitations of current stroke treatments, which are primarily effective for large vessel occlusions. The Rapid Medical TIGERTRIEVER device is designed to safely and effectively treat strokes and remove clots in smaller vessels deeper in the brain. The unique adjustability of the device allows physicians to control the size and force during a procedure, allowing for precise and safer clot removal in complex anatomies. Ronen explains, "So the quicker or the less time there is between the stroke and the ability to...
info_outlineEmpowered Patient Podcast
Robert Schickel, Chief Executive Officer at NUAgo Therapeutics, is developing a cancer therapy using short RNAs to target and disrupt interconnected survival genes in cancer cells. The therapy has been shown to be non-toxic to healthy cells, which have high levels of microRNAs, whereas cancer cells downregulate microRNAs to become metastatic. This is a systems-biology therapeutic approach that targets the entire survival network of a cell, making it independent of specific mutations or pathways and potentially applicable to the vast majority of solid tumors. Robert explains, "NUAgo is a...
info_outlineEmpowered Patient Podcast
Dr. Babak Saboury, Chief Scientific and Innovation Officer and Physician Founder of United Theranostics, discusses the emergence of nuclear oncology as the fourth pillar of cancer care. United Theranostics is combining advanced molecular imaging and radiopharmaceutical therapies to identify a cancer cell's unique fingerprint and then delivering targeted radiation, reducing side effects by sparing healthy cells. Molecular imaging can serve as a unifying map for guiding a collaborative, multimodal approach to treating a range of cancers. Babak explains, "I can just very quickly tell...
info_outlineEmpowered Patient Podcast
Dr. Babak Saboury, Chief Scientific and Innovation Officer and Physician Founder of United Theranostics, discusses the emergence of nuclear oncology as the fourth pillar of cancer care. United Theranostics is combining advanced molecular imaging and radiopharmaceutical therapies to identify a cancer cell's unique fingerprint and then delivering targeted radiation, reducing side effects by sparing healthy cells. Molecular imaging can serve as a unifying map for guiding a collaborative, multimodal approach to treating a range of cancers. Babak explains, "I can just very quickly tell...
info_outlineEmpowered Patient Podcast
Shaun Bagai, CEO of RenovoRx, has designed a drug-delivery platform to treat hard-to-reach chemo-resistant tumors such as pancreatic cancer by delivering chemotherapy directly to the tumor site. The RenovoCath device increases the drug concentration in the tumor while significantly reducing systemic toxicities and side effects. The technology is not intended to replace the traditional approach using systemic chemotherapy and radiation, but to achieve better results in tumors with low blood supply that prevent drugs from reaching their target in sufficient concentrations. Shaun explains,...
info_outlineDr. Mollie Leoni, Executive Vice President for Clinical Development of Kura Oncology, discusses the company's ziftomenib program, a menin inhibitor for acute myeloid leukemia (AML). The company initially allowed all AML patients to participate in the clinical study, but later found that specific subtypes, such as those with NPM1 mutation or KMT2A rearrangement, were more likely to respond to the menin inhibitor. They also discovered other subtypes that were responsive, expanding the potential patient population. Understanding the role of menin and menin inhibitors in addressing abnormal gene expression and promoting healthy cell development opens the door to potential combination therapy, where menin inhibitors could be layered onto existing treatments for various cancers related to menin independence.
Mollie explains, "In oncology, we have gotten good at treating the end state, but cancer has many, many causes with a common final endpoint to the way the cells look. So, it's many, many different diseases all at once. We've learned and are learning that with better technology and a better understanding of cancer in general we can identify not just how to stop the end state but how to stop it from starting."
"That's where ziftomenib comes in. Ziftomenib addresses key mutations that when they occur, are what cause the development of cancer. So you're able to shut down the development and force the cells to develop normally rather than waiting until they're already diseased and killing them with chemotherapy or some other cytotoxic agent."
"There is a protein complex that we refer to as the menin MLL complex, which goes rogue when something unusual happens in the cell. For example, that could be an NPM1 mutation. That could be a KMT2A rearrangement. Those are two things that are well-known to happen within AML diseases. It could also be a SETD2 RUNX1 mutation. So many types of mutations could happen that could cause this machinery to go rogue within the cell. And that complex causes genes to become active at levels and at times that are abnormal."
#KuraOncology #Ziftomenib #MeninInhibitors #PrecisionMedicine #BTD #AML
